Second cancers following pediatric Hodgkin's disease

Area of Science:

• Oncology
• Pediatric Oncology
• Cancer Epidemiology

Background:

• Hodgkin's disease is a cancer of the lymphatic system.
• Treatment for Hodgkin's disease has improved survival rates for pediatric patients.
• Long-term survivors may face an increased risk of developing secondary malignancies.

Purpose of the Study:

• To quantify the risk of second cancers in survivors of childhood Hodgkin's disease.
• To identify factors influencing the development of secondary cancers in this population.

Main Methods:

• A cohort of 694 pediatric Hodgkin's disease survivors was followed for up to 31.6 years.
• Relative risks (RRs), actuarial risks, and absolute excess risks for second malignancies were calculated.
• Multivariate analysis assessed the impact of sex, age, disease stage, splenectomy, treatment, and relapse on second cancer risk.

Main Results:

• Fifty-six patients developed 59 secondary malignancies, including solid tumors, leukemias, and non-Hodgkin's lymphomas.
• The overall relative risk for a second cancer was significantly elevated, particularly in females (RR=15.4).
• Relapse of Hodgkin's disease increased second malignancy risk (HR=2.6); chemotherapy was linked to subsequent leukemia.

Conclusions:

• While aggressive therapy cures Hodgkin's disease, survivors face a substantial risk of second cancers.
• Newer treatment strategies aim for cure with reduced radiation and alkylating agent chemotherapy.
• Lifelong surveillance and cancer screening are crucial for pediatric Hodgkin's disease survivors.